Resistance detection and re-treatment options in hepatitis C virus-related chronic liver diseases after DAA-treatment failure

Introduced in 2013–2014, the second- and third-wave directly acting antivirals (DAAs) have strongly enhanced the efficacy and tolerability of anti-HCV treatment, with a sustained virological response (SVR) in 90–95% of cases treated. The aim of this paper was to focus on the type and prevalence of viral strains with a reduced sensitivity to DAAs and on treatment choices for DAA-experienced patients. The Medline was searched for “HCV infection”,...